Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 17:23:100220.
doi: 10.1016/j.ahjo.2022.100220. eCollection 2022 Nov.

CXCL5 gene polymorphisms and coronary collateralization

Ellen C Keeley  1   2 , Michael R Blotner  1 , Lewis C Lipson  3 , Borna Mehrad  1   4
Affiliations

CXCL5 gene polymorphisms and coronary collateralization

Ellen C Keeley et al. Am Heart J Plus. .

Abstract

Background: The presence of coronary collateralization is heterogenous, even amongst those with similar degrees of epicardial coronary artery stenoses. We hypothesized that genetic variation of CXCL5, a chemokine that mediates angiogenesis, is associated with coronary collateralization.

Methods: We genotyped subjects undergoing coronary angiography for single nucleotide polymorphisms of CXCL5 and determined the presence of spontaneously visible coronary collaterals.

Results: Subjects with collaterals had less angina (46 % vs 59 %, p = 0.006), and prior percutaneous coronary intervention (34 % vs 47 %, p = 0.010), and more hyperlipidemia (90 % vs 82 %, p = 0.018), peripheral arterial disease (25 % vs 17 %, p = 0.041), congestive heart failure (16 % vs 8 %, p = 0.007), and multi-vessel coronary artery disease (41 % vs 24 %, p = 0.0001) compared to those without collaterals. Multi-vessel disease and hyperlipidemia were positive predictors of angiographically visible collaterals while being a carrier of the CXCL5 polymorphism was a negative predictor.

Conclusions: Coronary collateralization may, at least in part, be genetically determined.

Keywords: CXCL5 single nucleotide polymorphism; Coronary collaterals.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

    1. Regieli J.J., Jukema J.W., Nathoe H.M., Zwinderman A.H., Ng S., Grobbee D.E., van der Graaf Y., Doevendans P.A. Coronary collaterals improve prognosis in patients with ischemic heart disease. Int. J. Cardiol. 2009;132:257–262. - PubMed
    1. Koerselman J., de Jaegere P.P., Verhaar M.C., Grobbee D.E., van der Graaf Y. Prognostic significance of coronary collaterals in patients with coronary heart disease having percutaneous transluminal coronary angioplasty. Am. J. Cardiol. 2005;96:390–394. - PubMed
    1. Keeley E.C., Mehrad B., Strieter R.M. Chemokines as mediators of neovascularization. Arterioscler. Thromb. Vasc. Biol. 2008;28:1928–1936. - PMC - PubMed
    1. Strieter R.M., Polverini P.J., Kunkel S.L., Arenberg D.A., Burdick M.D., Kasper J., Dzuiba J., Van Damme J., Walz A., Marriott D., Chan S.Y., Roczniak S., Shanafelt A.B. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem. 1995;270:27348–27357. - PubMed
    1. Keeley E.C., Moorman J.R., Liu L., Gimple L.W., Lipson L.C., Ragosta M., Taylor A.M., Lake D.E., Burdick M.D., Mehrad B., Strieter R.M. Plasma chemokine levels are associated with the presence and extent of angiographic coronary collaterals in chronic ischemic heart disease. PLoS ONE. 2011;6 - PMC - PubMed

LinkOut - more resources